Literature DB >> 10231841

Ligand induced upregulation of the type II transforming growth factor (TGF-beta) receptor enhances TGF-beta responsiveness in COLO-357 cells.

J Kleeff1, S Wildi, H Friess, M Korc.   

Abstract

The effects of transforming growth factor (TGF)-beta 1 on type I and type II TGF-beta receptor (T beta RI and T beta RII) expression were examined in five pancreatic cancer cell lines. In contrast to its actions in COLO-357, a TGF-beta-sensitive pancreatic cancer cell line, TGF-beta 1 did not significantly alter TGF-beta receptor expression in either the TGF-beta-sensitive BXPC-3 and PANC-1 cells or in the TGF-beta-resistant CAPAN-1 and T3M4 cells. Neutralizing anti-T beta RII antibodies blocked TGF-beta 1-dependent signaling in COLO-357 cells but exhibited an attenuated effect in COLO-357 cells preincubated with TGF-beta 1 for 48 h. Basal T beta RII expression levels were comparable in all five cell lines examined. In contrast, COLO-357 cells and BX-PC-3 cells expressed relatively high basal levels of T beta RI. However, COLO-357 cells harbored a normal Smad4 gene, whereas BX-PC-3 cells exhibited a complete deletion of this gene. We conclude that the TGF-beta 1-induced T beta RII upregulation serves to enhance TGF-beta 1 responsiveness in COLO-357 cells, and that this upregulation requires the presence of adequate levels of T beta RI and T beta RII, and a functional Smad4 gene product. Our findings also indicate that TGF-beta 1 may inhibit pancreatic cancer cell growth via a Smad4-independent pathway.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10231841     DOI: 10.1097/00006676-199905000-00006

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  7 in total

1.  Restoration of Smad4 in BxPC3 pancreatic cancer cells attenuates proliferation without altering angiogenesis.

Authors:  Michiya Yasutome; Jason Gunn; Murray Korc
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  The Notch signaling pathway is related to neurovascular progression of pancreatic cancer.

Authors:  Peter Büchler; Amiq Gazdhar; Mario Schubert; Nathalia Giese; Howard A Reber; Oscar J Hines; Thomas Giese; Güralp O Ceyhan; Michael Müller; Markus W Büchler; Helmut Friess
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

3.  A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.

Authors:  Lorenzo F Sempere; Jason R Gunn; Murray Korc
Journal:  Cancer Biol Ther       Date:  2011-08-01       Impact factor: 4.742

4.  Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs.

Authors:  J G Lunz; S Contrucci; K Ruppert; N Murase; J J Fung; T E Starzl; A J Demetris
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

5.  RUNX3 expression in primary and metastatic pancreatic cancer.

Authors:  J Li; J Kleeff; A Guweidhi; I Esposito; P O Berberat; T Giese; M W Büchler; H Friess
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

6.  Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.

Authors:  Yuichi Akatsu; Yasuhiro Yoshimatsu; Taishi Tomizawa; Kazuki Takahashi; Akihiro Katsura; Kohei Miyazono; Tetsuro Watabe
Journal:  Cancer Sci       Date:  2017-01       Impact factor: 6.716

7.  Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer.

Authors:  Jian-Wei Xu; Tian-Xiao Wang; Lei You; Lian-Fang Zheng; Hong Shu; Tai-Ping Zhang; Yu-Pei Zhao
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.